Theodore Karrison

3.7k total citations · 1 hit paper
64 papers, 2.6k citations indexed

About

Theodore Karrison is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Theodore Karrison has authored 64 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Theodore Karrison's work include Lung Cancer Treatments and Mutations (8 papers), Renal cell carcinoma treatment (7 papers) and Cancer Treatment and Pharmacology (7 papers). Theodore Karrison is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Renal cell carcinoma treatment (7 papers) and Cancer Treatment and Pharmacology (7 papers). Theodore Karrison collaborates with scholars based in United States, Canada and Poland. Theodore Karrison's co-authors include Mark J. Ratain, Everett E. Vokes, Linda Janisch, Gini F. Fleming, Jacqueline Ramı́rez, Soma Das, Lalitha Iyer, Chun‐Su Yuan, Peter J. Dawson and Richard L. Schilsky and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Circulation.

In The Last Decade

Theodore Karrison

62 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

2002 521 citations Soma Das, Linda Janisch et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Theodore Karrison United States	26	1.1k	927	507	486	350	64	2.6k
Rudolf Maibach Switzerland	33	1.6k 1.5×	697 0.8×	1.2k 2.4×	864 1.8×	656 1.9×	73	3.7k
Hitoshi Kohno Japan	40	740 0.7×	1.2k 1.3×	1.5k 3.0×	846 1.7×	802 2.3×	135	5.2k
Wataru Habano Japan	27	747 0.7×	848 0.9×	447 0.9×	312 0.6×	571 1.6×	102	2.1k
Yu Sunakawa Japan	25	1.2k 1.1×	465 0.5×	256 0.5×	518 1.1×	341 1.0×	183	1.8k
Shigemitsu Takashima Japan	30	1.6k 1.4×	435 0.5×	497 1.0×	1.1k 2.3×	489 1.4×	158	3.4k
Horst Schran United States	28	1.1k 1.0×	626 0.7×	268 0.5×	405 0.8×	72 0.2×	70	3.0k
Kyung Hwan Kim South Korea	26	994 0.9×	429 0.5×	563 1.1×	485 1.0×	326 0.9×	95	2.2k
Antonio Nocito Switzerland	23	1.0k 0.9×	938 1.0×	1.0k 2.0×	465 1.0×	312 0.9×	59	2.9k
Jyh‐Cherng Yu Taiwan	38	1.0k 0.9×	1.8k 2.0×	880 1.7×	435 0.9×	811 2.3×	147	4.0k
C. Redaelli Switzerland	23	1.0k 0.9×	428 0.5×	1.0k 2.0×	707 1.5×	188 0.5×	49	2.4k

Countries citing papers authored by Theodore Karrison

Since Specialization

Citations

This map shows the geographic impact of Theodore Karrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Theodore Karrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Theodore Karrison more than expected).

Fields of papers citing papers by Theodore Karrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Theodore Karrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Theodore Karrison. The network helps show where Theodore Karrison may publish in the future.

Co-authorship network of co-authors of Theodore Karrison

This figure shows the co-authorship network connecting the top 25 collaborators of Theodore Karrison. A scholar is included among the top collaborators of Theodore Karrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Theodore Karrison. Theodore Karrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Anand, Adam DuVall, Caner Saygin, et al.. (2024). Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood. 144(Supplement 1). 1432–1432. 2 indexed citations

Rosenberg, Ari J., Theodore Karrison, Jonas A. de Souza, et al.. (2023). A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Annals of Oncology. 34(8). 714–722. 2 indexed citations

Olson, Daniel J., Zeynep Eroglu, Bruce Brockstein, et al.. (2021). Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of Clinical Oncology. 39(24). 2647–2655. 136 indexed citations

Mansour, Ali, Andrea Loggini, Fernando D. Goldenberg, et al.. (2020). Coagulopathy as a Surrogate of Severity of Injury in Penetrating Brain Injury. Journal of Neurotrauma. 38(13). 1821–1826. 7 indexed citations

Ollech, Jacob E., Roni Weisshof, Laura Glick, et al.. (2019). Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn’s disease. Gastrointestinal Endoscopy. 90(2). 269–275. 35 indexed citations

Arina, Ainhoa, et al.. (2017). Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1–Resistant Tumors Leading to Tumor Eradication. Cancer Immunology Research. 5(2). 127–136. 14 indexed citations

Choudhury, Noura J., Tatjana Antic, Kai Lee Yap, et al.. (2016). Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. Journal of Clinical Oncology. 34(18). 2165–2171. 125 indexed citations

Odenike, Olatoyosi, Anna B. Halpern, Lucy A. Godley, et al.. (2014). A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs. 33(2). 371–379. 10 indexed citations

Tan, Yi‐Hung Carol, Soundararajan Krishnaswamy, Suvobroto Nandi, et al.. (2010). CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases. PLoS ONE. 5(1). e8972–e8972. 84 indexed citations

10.

Wroblewski, Keith J., Laura Sit, Theodore Karrison, et al.. (2010). Use of typical in-patient blood pressure measurements to detect bevacizumab-induced elevation in systolic pressure after the first infusion.. Journal of Clinical Oncology. 28(15_suppl). e13622–e13622. 1 indexed citations

11.

Posadas, Edwin M., et al.. (2010). A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Carcinoma. American Journal of Clinical Oncology. 34(2). 150–154. 8 indexed citations

12.

Sher, Dorie, Theodore Karrison, Partow Kebriaei, et al.. (2008). Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leukemia & lymphoma. 49(3). 531–537. 6 indexed citations

13.

Rudin, Charles M., Wanqing Liu, Apurva A. Desai, et al.. (2008). Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity. Journal of Clinical Oncology. 26(7). 1119–1127. 186 indexed citations

14.

Peterson, Amy, Helena Harlin, Theodore Karrison, et al.. (2006). A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Investigational New Drugs. 24(2). 141–149. 17 indexed citations

15.

Yuan, Chun‐Su, Michael O’Connor, Theodore Karrison, et al.. (2005). Tolerability, Gut Effects, and Pharmacokinetics of Methylnaltrexone Following Repeated Intravenous Administration in Humans. The Journal of Clinical Pharmacology. 45(5). 538–546. 75 indexed citations

16.

Yuan, Chun‐Su, Gang Wei, Joseph Foss, et al.. (2002). Effects of Subcutaneous Methylnaltrexone on Morphine-Induced Peripherally Mediated Side Effects: A Double-Blind Randomized Placebo-Controlled Trial. Journal of Pharmacology and Experimental Therapeutics. 300(1). 118–123. 94 indexed citations

17.

Draganich, Louis F., James P. Zacny, Jerome M. Klafta, & Theodore Karrison. (2001). The Effects of Antidepressants on Obstructed and Unobstructed Gait in Healthy Elderly People. The Journals of Gerontology Series A. 56(1). M36–M41. 34 indexed citations

18.

Tripathi, Ramesh C., Barbara S. Kirschner, Brenda J. Tripathi, et al.. (1992). Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology. 102(6). 1957–1961. 58 indexed citations

19.

Elliott, W.J. & Theodore Karrison. (1991). Increased all-cause and cardiac morbidity and mortality associated with the diagonal earlobe crease: A prospective cohort study. The American Journal of Medicine. 91(3). 247–254. 47 indexed citations

20.

Karrison, Theodore. (1990). Bootstrapping censored data with covariates. Journal of Statistical Computation and Simulation. 36(4). 195–207. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact